Time Schedule
Monday, April 09 19:30-20:30 Opening Ceremony | 20:30-21:00 Keynote Speaker | 21:00-21:30 Discussion | 22:00 Dinner | Tuesday, April 10 07:00-08:00 Breakfast / Registration | 1st Session: Acute Coronary Syndrome (ACS): 08:00-09:15 | 08:00-08:25 Acute Coronary Syndrome Management: Current Challenges and Emerging Solutions. | 08:25-08:50 Dug Eluting Stent: An Update on Clinical Data. | 08:50-09:05 Antiplatelet Strategies in Acute Coronary Syndrome: Expanding Choices. | 09:15-09:30 Discussion | 09:30-09:40 Break | 2nd Session: Evolution of Antithrombotic Therapy Use in Acute Coronary Syndrome: 09:40-10:45 | 9:40-10:05 Anticoagulant in ACS and Beyond. | 10:05-10:30 Newer Antiplatelet: Confronting the Limitations of Antiplatelet Therapy. | 10:30-10:55 Risk of Bleeding: Balancing Risk and Benefit. | 10:55-11:10 Discussion | 11:10-11:20 Break | 3rd Session: Heart Failure (HF): 11:20-12:15 | 11:20-11:45 Heart Failure: Current Medical Therapy. | 11:45-12:10 Heart Rate as a Therapeutic Target in Heart Failure Patients. | 12:10-12:35 Devices and Technology in the Management of Heart Failure. | 12:35-12:50 Discussion | 12:50-14:00 Prayer Time, Lunch Break, Exhibition | 4th Session: Hypertension: 14:00-16:00 | 14:00-14:25 Update on Hypertension Management. | 14:25-14:50 JNC 8 (VIII): What is new going to be in the guidelines? | 14:50-15:15 Strategies for the Management of Resistant Hypertension. | 15:15-15:30 Discussion, Prayer Time | 5th Session: Ambulatory care in Cardiology: 15:30-16:45 | 15:30-15:55 Medication safety concerns in the cardiovascular patient. | 15:55-16:20 Lipid management: Optimizing Therapies Old and New. | 16:20-16:45 Primary prevention of cardiovascular disease: Tools and Strategies. | 16:45-17:00 Discussion | Wednesday, April 11 07:00-08:00 Breakfast / Registration | 1st Session: Atrial fibrillation (Afib): 08:00-09:15 | 08:00-08:25 Contemporary approach in Atrial Fibrillation Management. | 08:25-08:50 Antithrombotic Therapy in Afib: Defining the future of Oral Anticoagulant Therapy. | 08:50-09:15 Combined Atrial Fibrillation and Heart Failure: Challenges in Pharmacotherapy Management. | 09:15-09:30 Discussion | 09:30-09:40 Break | 2nd Session: End stage Heart Failure and Heart Transplant: 09:30-10:45 | 09:40-10:05 ICU Management of End Stage Heart Failure and Mechanical Circulatory Support Therapy. | 10:05-10:30 Heart Transplant: indication, selection, pre and post op care. | 10:30-10:55 Long Term Management of Heart Transplant and the Pharmacist Role. | 10:55-11:10 Discussion | 11:10-11:20 Break | 3rd Session: Venous Thromboembolism (VTE) Challenge and Valvular Heart Disease (VHD) Management: 11:00-12:15 | 11:20-11:45 VTE: Acute and Chronic Management. | 11:45-12:10 Contemporary Management of VHD in Various Medical Settings. | 12:10-12:35 Transcatheter Aortic Valve Implantation (TAVI): Highlight on Procedural and Pharmacotherapy Management Implications. | 12:35-12:50 Discussion | 12:50-14:00 Prayer Time, Lunch Break, Exhibition | 4th Session: Personalized Medicine in Cardiology: 14:00-16:00 | 14:00-14:25 Antiplatelet resistant / un-responsiveness: Genomic Markers and Advanced Testing. | 14:25-14:50 Tailored antiplatelet therapy: Pharmacogenomics or Dynamic Applications? | 14:50-15:15 Women cardiology: Differences in Diagnosis and Management. | 15:15-15:30 Discussion, Prayer | 5th Session: Pulmonary Hypertension: 15:30-16:45 | 15:30-15:55 Diagnosis and Treatment of Pulmonary Hypertension. | 15:55-16:20 Pulmonary Hypertension in ICU Setting. | 16:20-16:45 Perspectives on Pharmacoeconomic Appropriateness of Pulmonary Hypertension Medications. | 16:45-17:00 Discussion | 17:00-17:30: Closing Ceremony
Slider

Our 2nd International Cardiovascular Pharmacotherapy Conference & Exhibition 2012 with the theme “ Prospect and Challenge of Cardiovascular  Pharmacotherapy” which organize by pharmacy services department in Prince Sultan Cardiac Center, Riyadh, Saudi Arabia, will strive to present topics that highlight new evidence-based medicine findings reported within the last one to two years that impact cardiovascular clinical practice. These will range across a variety of cardiologic topics including preventive cardiology, thromboembolic disease, interventional cardiology, ischemic heart disease, electrophysiology, heart failure, pulmonary hypertension, heart transplantation, women cardiology, personalized medicine and hypertension.

This update in cardiology is an educational initiative featuring sessions each focusing on a different cardiology related topic. The curriculum is based on recent updates and designed to change audience competence, performance and patient outcomes through a series of lectures, interactive discussion, and workshops. The focus is on clinical implications of recent pivotal trial data, discussion of topics and issues most relevant to the practicing cardiologist, practical insights you can apply immediately in practice. The treatments and therapies we will learn about in this symposium will improve our patients' care tomorrow.

Our faculty will include a distinguished group of visiting academicians and clinicians from North America together with outstanding local clinicians. We plan to offer adequate time after each set of lectures in a given topic area to permit a panel discussion as well as to extend to our attendees the opportunity to comment and/or to direct questions to the faculty.

The conference will last 2 days  and is designed to appeal to a broad audience of Cardiovascular Physicians, Clinical Pharmacists, Pharmacists, Nurses, Technicians, Others interested in cardiovascular Pharmacotherapy and other relevant health care professionals, promoting interaction among participants from diverse disciplines through lectures, discussions, workshops, and informal interactions. The intimate audience size and classroom setting facilitate a high level of interaction among and between attendees and faculty. Participants will have the opportunity to ask questions specific to challenges encountered in their daily practice. We expect an exciting exchange of ideas, new collaborations to be initiated, and a greater understanding of the most promising treatment strategies that could alter our approach to patients with cardiovascular diseases. 

Program overview:

This program addresses the need to renew and update the pharmacotherapy of selected topics in cardiovascular diseases. This symposium is to provide a comprehensive review of the most important advances that have recently been made in cardiovascular pharmacotherapy. The emphasis will be placed on progress that has been made in epidemiology, pathophysiology and clinical management of the most common disorders. The program includes a variety of lectures, panel discussions, and workshops. 

Program location:

The conference will be held in the Four Seasons Hotel, Kingdom Center in Riyadh, Saudi Arabia. The program will open on Monday 09 April at19:30 (keynote speaker) and Close on Wednesday 11 April at 16:30. 

Who should attend?

The audience will consist of clinical pharmacists, cardiovascular physicians, pharmacists, and other relevant health care professionals.

Continuous Education Hours:

This symposium will be accredited by the Saudi Health Council for continuous education. All faculties participating in this symposium will disclose to the audience (1) significant financial relationships with the manufacturer(s) of products from the commercial supporter(s) and/or manufacturer(s) of products or devices discussed in their presentation and (2) unlabeled/unapproved uses of drugs or devices discussed in their presentation. Such disclosures will be made in writing in course presentation materials.

Sponsors